Seres Stops Enrollment In Melanoma Study, Deprioritizes Further Development

by Vandana Singh, Benzinga Editor

March 8, 2021 8:35 AM | 1 min read |

Seres Therapeutics Inc (NASDAQ: MCRB) and its study partners have voluntarily discontinued further enrollment in the Phase 1 study evaluating SER-401 in metastatic melanoma.
The company cited challenges related to the pandemic.
The study was assessing the safety and drug activity of SER-401 or fecal microbiota transplant (FMT) in combination with nivolumab.
A preliminary analysis of results from 10 subjects indicated that SER-401 was safe and well-tolerated.
No patients were enrolled in the FMT portion of the study.
Subjects currently enrolled in the study will complete the study protocol.
Price Action: MCRB shares gained 0.73% at $19.2 in premarket trading on the last check Monday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.